Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Pfizer announced a landmark agreement with the U.S. government, which is set to provide clarity on future innovation and growth. This agreement includes a 3-year grace period from certain U.S. tariffs ...

As the prospect of import tariffs and drug price reform marshals billions of biopharma investment dollars into the U.S., the ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for ...

The European Union reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the ...

The dramatic bidding war kicked off last week with Novo's surprise play for Metsera, which had already agreed to be acquired ...

Wall Street analysts also expect sales of the COVID-19 vaccine Spikevax from Moderna to tumble about 50% in the third quarter ...

A second magnificent ultra-high-yield dividend stock that's begging to be bought in November is pharmaceutical titan Pfizer ( ...